ONO PHARMACEUT.
Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules f… Read more
ONO PHARMACEUT. (ON4) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ONO PHARMACEUT. (ON4) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ONO PHARMACEUT. - Net Assets Trend (None–None)
This chart illustrates how ONO PHARMACEUT.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ONO PHARMACEUT. (None–None)
The table below shows the annual net assets of ONO PHARMACEUT. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ONO PHARMACEUT.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ONO PHARMACEUT. Competitors by Market Cap
The table below lists competitors of ONO PHARMACEUT. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Chewy Inc
NYSE:CHWY
|
$5.96 Billion |
|
GD Power Development Co Ltd
SHG:600795
|
$5.96 Billion |
|
Chord Energy Corp
NASDAQ:CHRD
|
$5.96 Billion |
|
Transocean Ltd
NYSE:RIG
|
$5.97 Billion |
|
ARCADIUM LITHIUM CDI/1
F:7WO
|
$5.96 Billion |
|
Tongwei Co Ltd
SHG:600438
|
$5.96 Billion |
|
Matador Resources Company
NYSE:MTDR
|
$5.95 Billion |
|
Hyatt Hotels Corporation
NYSE:H
|
$5.95 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ONO PHARMACEUT.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ONO PHARMACEUT.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ONO PHARMACEUT. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ONO PHARMACEUT.'s net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $490,513,044,000
- Average return on equity (ROE) among peers: -13.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ONO PHARMACEUT. (ON4) | €- | N/A | N/A | $5.96 Billion |
| Bayer Aktiengesellschaft (BAYA) | $30.70 Billion | -34.19% | 2.81x | $9.78 Billion |
| EH3 (EH3) | $486.18 Million | -16.90% | 0.41x | $245.45 Million |
| JCR Pharmaceuticals Co., Ltd. (JCR) | $47.44 Billion | -10.03% | 1.21x | $237.56 Million |
| Otsuka Holdings Co. Ltd (OS1) | $1.88 Trillion | 7.87% | 0.40x | $26.35 Billion |